MX2020008546A - Composicion farmaceutica que comprende remogliflozina y un agente antidiabetico. - Google Patents

Composicion farmaceutica que comprende remogliflozina y un agente antidiabetico.

Info

Publication number
MX2020008546A
MX2020008546A MX2020008546A MX2020008546A MX2020008546A MX 2020008546 A MX2020008546 A MX 2020008546A MX 2020008546 A MX2020008546 A MX 2020008546A MX 2020008546 A MX2020008546 A MX 2020008546A MX 2020008546 A MX2020008546 A MX 2020008546A
Authority
MX
Mexico
Prior art keywords
remogliflozin
pharmaceutically acceptable
antidiabetic agent
acceptable salt
pharmacutical composition
Prior art date
Application number
MX2020008546A
Other languages
English (en)
Inventor
Ulhas Dhuppad
Nitin Deshmukh
Krishna Sadaphal
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of MX2020008546A publication Critical patent/MX2020008546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende remogliflozina o sal o éster farmacéuticamente aceptable de la misma y metformina o sal farmacéuticamente aceptable de la misma. En particular, se refiere a una composición farmacéutica de liberación inmediata que comprende: (a) remogliflozina o sal o éster farmacéuticamente aceptable de la misma, (b) metformina o sal farmacéuticamente aceptable de la misma y (c) un excipiente farmacéuticamente aceptable.
MX2020008546A 2018-02-21 2019-02-12 Composicion farmaceutica que comprende remogliflozina y un agente antidiabetico. MX2020008546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821006578 2018-02-21
PCT/IB2019/051116 WO2019162800A1 (en) 2018-02-21 2019-02-12 Pharmacutical composition comprising remogliflozin and antidiabetic agent

Publications (1)

Publication Number Publication Date
MX2020008546A true MX2020008546A (es) 2021-01-08

Family

ID=67687425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008546A MX2020008546A (es) 2018-02-21 2019-02-12 Composicion farmaceutica que comprende remogliflozina y un agente antidiabetico.

Country Status (7)

Country Link
KR (1) KR20200035437A (es)
CN (1) CN111246917A (es)
BR (1) BR112020017056A2 (es)
MX (1) MX2020008546A (es)
PH (1) PH12020500228A1 (es)
RU (1) RU2019144196A (es)
WO (1) WO2019162800A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588713B (zh) * 2020-06-22 2021-03-09 广州市力鑫药业有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2022263935A1 (en) * 2021-06-14 2022-12-22 Glenmark Pharmaceutical Limited Pharmacutical composition comprising remogliflozin etabonate, metformin hydrochloride and vildagliptin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
BR112012011733A2 (pt) * 2009-11-13 2019-09-24 Bristol-Myers Squibb Company formulações de comprimido de liberação imediata
CN104586834A (zh) * 2014-12-12 2015-05-06 周连才 一种艾帕列净和二甲双胍的药物组合物及其制备方法
CN110753540A (zh) * 2017-06-08 2020-02-04 格兰马克药品有限公司 瑞格列净的口服药物制剂

Also Published As

Publication number Publication date
RU2019144196A (ru) 2021-06-28
CN111246917A (zh) 2020-06-05
WO2019162800A1 (en) 2019-08-29
KR20200035437A (ko) 2020-04-03
BR112020017056A2 (pt) 2020-12-15
RU2019144196A3 (es) 2021-06-28
PH12020500228A1 (en) 2020-11-09

Similar Documents

Publication Publication Date Title
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
PH12019500579A1 (en) Pharmaceutical composition
NZ763551A (en) Compounds useful for inhibiting cdk7
SG11201811697SA (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
MX2019003099A (es) Composicion farmaceutica.
EP4041734C0 (en) DERIVATIVES CONTAINING 1,2,3,4-TETRAHYDRONAPHTHALENE UNIT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
PH12020500228A1 (en) Pharmacutical composition comprising remogliflozin and antidiabetic agent
MX2020012989A (es) Agente terapeutico para la fibrosis.
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
WO2019194773A3 (en) The combination comprising linagliptin and metformin
IL288645A (en) Conjugated saponin and vaccine or a pharmaceutical composition containing it
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
MX2021010022A (es) Composicion farmaceutica.
MX356789B (es) Composición de difenidol de liberación prolongada.
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
GEP20217301B (en) Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2019074464A3 (en) The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5